Cancer Supportive Care Drugs Market 2019 | See Incredible Growth by Top Players Novartis AG, F.Hoffmann La-Roche Ltd., Amgen, Inc., Baxter International, Inc., Teva Pharmaceutical Industries Ltd., Acacia Pharma Ltd., Merck & Co., Inc., Helsinn Healthcare

High prevalence of various types of cancer is a key factor supporting growth of the global cancer supportive care drugs market. Cancer is one of the most prevalent fatal chronic disorders with a high mortality rate due to its invasive nature and prolonged duration of disease. According to National Cancer Institute, around 1,735,350 new cancer cases are expected to be diagnosed in the U.S. in 2018. The most common cancers are lung cancer, breast cancer, prostate cancer, melanoma, bladder cancer, and others.

Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/2013

Cancer treatment includes chemotherapy, radiation therapy, targeted therapy, hormone replacement therapy, and others. These therapies have their own advantages and side effects. Cancer supportive care drugs are primarily used to aid in treatment of side effects associated with various cancer treatments. Increasing demand for various cancer therapies, owing to high prevalence of the disease is expected to boost the global cancer supportive care drugs market growth over the forecast period. According to American Cancer Society, in 2017, around 222,500 new cases of lung cancer were registered and around 155,870 deaths recorded due to lung cancer in the U.S.

Moreover, drugs such as erythropoietin stimulating agents are on the World Health Organizations’ (WHO) essential medicine list, indicated for the treatment of anemia due to chemotherapy and other treatments. Effectiveness of biopharmaceutical drugs such as erythropoietin stimulating agents and g-colony stimulating factors in the treatment of cancer induced side effects (anemia) is expected to propel the global cancer supportive care drugs market growth over the forecast period.

However, biosimilar launches (as biosimilars are cheaper) in categories such as erythropoietin stimulating agents and g-colony stimulating factors is expected to restrain the global cancer supportive care drugs market growth over the forecast period. For instance, the U.S. Food & Drug Administration (FDA) recommended approval of Hospira’s Epogen biosimilar in 2017. Sandoz launched Zarxio (Filgrastim-sndz), a biosimilar of Filgrastim in 2015.

Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2013

Government organizations and institutions are focusing on promoting better palliative/supportive care to improve patients’ quality of life. For instance, the American Cancer Society has collaborated with various institutions such as National Palliative Care Research Center (NPCRC) (in 2007) to improve cancer supportive care and to promote palliative care. Moreover, the American Cancer Society Cancer Action Network (ACS CAN) is working to improve access to palliative care services for adults and children that are severely suffering from various types of cancer.

Key players operating in the cancer supportive care drugs market include Johnson & Johnson, Novartis AG, F.Hoffmann La-Roche Ltd., Amgen, Inc., Baxter International, Inc., Teva Pharmaceutical Industries Ltd., Acacia Pharma Ltd., Merck & Co., Inc., Helsinn Healthcare SA, and Heron Therapeutics.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.